News

A highlighted description of some key takeaways from presentations at Pri-Med Midwest 2022, including such topics as infectious disease, monkeypox, colorectal cancer, psoriasis, and COVID-19.

Several factors that impaired healing included former smoking and seton insertion.

The Recap of Atopic Eczema (RECAP) and Atopic Dermatitis Control Tool (ADCT) were recommended to measure eczema control.

AI-enabled retinal imaging can accurately predict CVD and death, without the need for blood tests or BP measurement, according to the findings.

Fifteen out of 17 studies in a systematic review indicated that the HRD number decreased after DME treatment.

As the age of diagnosis for pre and type 2 diabetes continues to decrease, Dr. Tina Thethi believes in focusing on reducing risk factors to prevent further complications.

Dr. Veronica Anwuri discusses how apremilast (Otezla), the first oral, non biologic treatment option for plaque psoriasis can address the systemic pain associated with psoriatic arthritis.

The ongoing buzz around GLP-1 RAs, like semaglutide, and now the GIP combination drug tirzepatide, reached a summit at Pri-Med Midwest 2022.

"When you decrease the weight, that also improves the metabolic parameters. The A1c goes down, it helps bring the fasting glucose down, including even liver parameters," she explained.

An interview with Dr. Anwuri regarding her Pri-Med Midwest presentation on treating adult plaque psoriasis.

Semaglutide (Wegovy) has drawn attention for its indication of weight loss. Recently, however, the focus has shifted to the data surrounding tirzepatide.

Despite the efforts to increase the affordability of GLP-1 receptor agonists cost-effectiveness is still a barrier for many patients living with diabetes looking for effective therapies.

In an interview during Pri-Med Midwest, Dr. Kushner spoke about the benefits of treating obesity and diabetes synchronously.

A discussion with Dr. Vega regarding colorectal cancer screenings, aspirin use recommendations, and the current state of healthcare.

Primary Care Physicians (PCPs) play a crucial role in endorsing lifestyle counseling and facilitating integrative care for their patients.

An interview with Dr. Vega regarding atrial fibrillation and clinical manifestations for ADPKD.

Women who were socially isolated were more likely to have insomnia than women who were socially integrated.

A post-AAO 2022 discussion on avacincaptad pegol in GA and what this groundbreaking treatment represents in filling a currently unmet need.

The beneficial effect of intensive BP control on cardiovascular and all-cause mortality was attenuated during 4.5 years of post-trial after SPRINT.

A discussion with Dr. Angarone regarding his presentation at Pri-Med Midwest, exploring the topic of treating infectious disease in developing countries.

A discussion regarding highlights from Dr. Charles Vega’s presentation on common urgent care presentations and concerns regarding acute pain.

"Less than 2 or 3% of individuals with obesity—who are candidates for pharmacotherapy—actually receive a medication," Dr. Robert Kushner explains in an interview.

A cross-sectional analysis from the France COVID-19 lockdown period resulted in a predictive model for insomnia risk.

Dr. Angarone highlighted several key takeaways from his presentation at Pri-Med Midwest.

Overall, secukinumab was more effective in biologic-naïve patients and in patients with a lower body mass index (BMI).

The glycemic gap was a stronger predictor of in-hospital mortality among adults with diabetes or hyperglycemia hospitalized for COVID-19.

The Qazi Corner will be a quarterly newsletter led by Taha Qazi, MD, of the Cleveland Clinic and featuring new data, conference highlights, and perspectives of leading gastroenterologists.

In this special edition episode of Diabetes Dialogue, our hosts break down their top clinical takeaways from the European Association for the Study of Diabetes 2022 annual meeting, new data from the FLASH-UK trial, the global launch of Dexcom G7, and the announcement of US availability for the FreeStyle Libre 3.

Paxlovid is effective in patients with existing heart disease, but has significant DDIs with commonly used cardiovascular medications.

A discussion regarding highlights from Dr. Michael Angarone’s presentation on emerging infectious diseases.